Plain-English translation of NCT03184753 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of immunotherapy called —genetically engineered immune cells designed specifically to recognize and attack ovarian cancer. Researchers take immune cells from your own body, modify them in the laboratory to better fight your cancer, and then give them back to you. The study aims to see whether this approach is safe and whether it can help control or shrink ovarian cancer.
Ovarian cancer is a serious disease, and standard treatments like surgery and chemotherapy don't always work for everyone, especially for cancers that come back after initial treatment. This trial exists because scientists believe that training your own immune system to target cancer cells more precisely could offer a new hope for patients whose cancers have recurred or are hard to treat.
You likely qualify if…
You likely don't qualify if…
You would first have immune cells collected from your blood, which are then sent to the laboratory to be genetically modified. After the cells are ready, you would return to receive them back through an intravenous injection (into a vein) and possibly a direct injection into the tumor. You would be monitored closely with follow-up visits and blood tests to check how safe and effective the treatment is for you.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~100 participants
Started
May 2025
Primary completion
September 2028
Age range
18 Years – 65 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.